The Drug Development Authority of India (DDAI) has submitted its application for Phase 1 registration of ‘Prisma’ (cure vision) drug for the treatment of ‘curing’ blindness.
The application is being submitted to the National Pharmaceutical Control Organisation (NPCO) for review and approval by the government.
It is the second drug in a trial involving around 50 children in the U.K. where Prisma was shown to help improve vision in children with a severe form of cataract.
The drug has been approved for the prevention of catatonia in people with cataracts.
The trial was carried out at Queen Elizabeth Hospital, University College London and is supported by the British Foundation for Blind Children (BFB), the UCL Foundation, the National Eye Institute and the University of Birmingham.
The DDAI has said the drug could be available in India by the end of this year.
The Prisma Drug is the first of a series of drugs the agency hopes to patent in the near future.
It has also been announced that the drug will be marketed in the United States, where it is already approved.
It has been licensed to Eli Lilly and AstraZeneca.
The company said it has already received a licence from the US Food and Drug Administration (FDA) for its drug.